Watson Pharmaceuticals, Inc. , today announced that its subsidiary, Watson Laboratories, Inc., has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for desogestrel/ethinyl estradiol and ethinyl estradiol tablets, 0.15 mg / 0.02 mg and 0.01 mg and placebo tablets (28- day regimen).
The details can be read here.
No comments:
Post a Comment